Skip to Content

TEVA B1 (Letrozole 2.5 mg)

Pill with imprint TEVA B1 is Yellow, Round and has been identified as Letrozole 2.5 mg. It is supplied by Teva Pharmaceuticals USA Inc.

Letrozole is used in the treatment of breast cancer, metastatic; breast cancer, adjuvant; breast cancer and belongs to the drug classes aromatase inhibitors, hormones/antineoplastics. There is positive evidence of human fetal risk during pregnancy. Letrozole 2.5 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for TEVA B1

Letrozole 2.5 mg TEVA B1
Letrozole 2.5 mg TEVA B1 Front
Letrozole 2.5 mg TEVA B1 Back
Letrozole 2.5 mg TEVA B1

Letrozole

Imprint
TEVA B1
Strength
2.5 mg
Color
Yellow
Size
6.00 mm
Shape
Round
Availability
Prescription only
Drug Class
Aromatase inhibitors, Hormones/antineoplastics
Pregnancy Category
D - Positive evidence of risk
CSA Schedule
Not a controlled drug
Labeler / Supplier
Teva Pharmaceuticals USA Inc
Inactive Ingredients
silicon dioxide, FD&C Blue No. 2, indigotindisulfonate sodium, FD&C Yellow No. 5, ferric oxide yellow, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol 3350, polyethylene glycol 4000, sodium starch glycolate type A potato, corn starch, magnesium silicate, titanium dioxide

Note: Inactive ingredients may vary.

Labelers / Repackagers

NDC CodeLabeler / Repackager
00093-7620 Teva Pharmaceuticals USA, Inc.
42291-0374 AvKare, Inc.

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.